<DOC>
	<DOCNO>NCT00171288</DOCNO>
	<brief_summary>The objective study assess effect combination treatment C-reactive protein inflammatory marker well safety tolerability Spanish population</brief_summary>
	<brief_title>Efficacy Safety Study Fluvastatin Ezetimibe Combined Versus Fluvastatin Alone</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>Patients age 1875 Primary hypercholesterolemia Signed informed consent Patients involve clinical trial 3 month prior inclusion Patients treat drug specify protocol Fertile woman use contraceptive method Other protocol define exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Dyslipidemia , ezetimibe , inflammatory marker , fluvastatin</keyword>
</DOC>